The move also means it gets a platform to establish a presence on the North American market with a view to increasing its activities in this region.
The financial terms of the transaction were not disclosed.
Backed by healthcare investment fund, ArchiMed, the deal positions Biodextris for near-term expansion, said Joe Zimmermann, CEO of the Canadian CDMO. “We currently have clients in North America, Europe, and Asia, but the affiliation with Clean Biologics will likely broaden this base in the short-term.”
Based in Montreal, Biodextris is involved with upstream production processes; both microbial fermentation and mammalian cell culture, as well as downstream processes for the purification of biological products from microbial and mammalian cells and stabilized formulations of the purified material.
The contract development and manufacturing organization (CDMO) also develops analytical methods for the characterization and quality control testing of bulk drug substances and drug products comprised of material produced by the particular process.
In terms of the biologic products the Canadian firm has developed, manufactured, and tested for vaccine, pharmaceutical and other applications, Zimmermann told BioPharma-Reporter: “Biodextris has mainly produced protein drugs such as vaccine antigens, monoclonal antibodies, therapeutic proteins as well as whole cell therapeutic products. Recent examples include a SARS-CoV2 spike protein antigen for the University of Saskatchewan/VIDO Covid-19 vaccine, a bacterial derived immunotherapeutic agent for treatment of Alzheimer’s Disease (IMAB-Harvard University Medical School) and a recombinant protein antigen used in the development of a Hepatitis B vaccine for a major pharmaceutical company. We also has extensive experience in the analytical testing of hemagglutinin antigens and influenza vaccines.”